BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

...Colo. email: nathan.dahl@childrenscolorado.org CONTACT: Rajeev Vibhakar, same affiliation as above email: rajeev.vibhakar@ucdenver.edu Claire Quang alvocidib, flavopiridol (DSP-2033, hmr...
BioCentury | Aug 30, 2019
Clinical News

Aug. 30 Clinical Quick Takes: Pharnext falls on FDA request for second Phase III study, plus Genentech, Novartis and Seqirus

Pharnext shares sag on regulatory slowdown Shares of Pharnext S.A. (Euronext:ALPHA) lost €4.99 (41%) to €7.16 on Friday after the company said FDA advised it to conduct a second Phase III study of PXT3003 prior...
BioCentury | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Blocking pyrimidine synthesis via inhibition of CAD or DHODH, an enzyme downstream CAD, could treat glioblastoma. In patients, high tumor expression of a pyrimidine metabolism gene signature was associated...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BioCentury | May 20, 2019
Distillery Therapeutics

Aubagio and other DHODH inhibitors as epilepsy therapies

DISEASE CATEGORY: Neurology INDICATION: Epilepsy Patient sample, cell culture and mouse studies suggest inhibiting DHODH could help treat epilepsy. Metabolic modeling of transcriptome data from the cortex and hippocampus of epilepsy patients and two rat...
BioCentury | Feb 22, 2019
Emerging Company Profile

Gyroscope complements dry AMD

...one other company is developing a gene therapy for dry AMD. Hemera Biosciences Inc. has HMR-101...
BioCentury | Dec 22, 2016
Company News

Sumitomo acquiring Tolero

...Utah) for $200 million up front plus milestones. The deal provides Sumitomo with alvocidib (formerly HMR...
BioCentury | Sep 1, 2014
Clinical News

Alvocidib: Interim Phase II data

...Tolero Pharmaceuticals Inc. , Lehi, Utah Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alvocidib, flavopiridol (formerly HMR...
BioCentury | Apr 28, 2014
Clinical News

Alvocidib regulatory update

...Tolero Pharmaceuticals Inc. , Lehi, Utah Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alvocidib (flavopiridol) (formerly HMR...
BioCentury | Jan 6, 2014
Company News

Merck, HMR Weight Management Services Corp. endocrine/metabolic news

...On Dec. 20, 2013, Merck launched subsidiary HMR to provide weight management interventions that combine a...
...weight management interventions that combine a structured diet, behavior coaching and monitoring and physical activity. HMR...
...programs through a network of licensed clinics and through a remote delivery program. Merck said HMR...
Items per page:
1 - 10 of 316
BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

...Colo. email: nathan.dahl@childrenscolorado.org CONTACT: Rajeev Vibhakar, same affiliation as above email: rajeev.vibhakar@ucdenver.edu Claire Quang alvocidib, flavopiridol (DSP-2033, hmr...
BioCentury | Aug 30, 2019
Clinical News

Aug. 30 Clinical Quick Takes: Pharnext falls on FDA request for second Phase III study, plus Genentech, Novartis and Seqirus

Pharnext shares sag on regulatory slowdown Shares of Pharnext S.A. (Euronext:ALPHA) lost €4.99 (41%) to €7.16 on Friday after the company said FDA advised it to conduct a second Phase III study of PXT3003 prior...
BioCentury | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Blocking pyrimidine synthesis via inhibition of CAD or DHODH, an enzyme downstream CAD, could treat glioblastoma. In patients, high tumor expression of a pyrimidine metabolism gene signature was associated...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BioCentury | May 20, 2019
Distillery Therapeutics

Aubagio and other DHODH inhibitors as epilepsy therapies

DISEASE CATEGORY: Neurology INDICATION: Epilepsy Patient sample, cell culture and mouse studies suggest inhibiting DHODH could help treat epilepsy. Metabolic modeling of transcriptome data from the cortex and hippocampus of epilepsy patients and two rat...
BioCentury | Feb 22, 2019
Emerging Company Profile

Gyroscope complements dry AMD

...one other company is developing a gene therapy for dry AMD. Hemera Biosciences Inc. has HMR-101...
BioCentury | Dec 22, 2016
Company News

Sumitomo acquiring Tolero

...Utah) for $200 million up front plus milestones. The deal provides Sumitomo with alvocidib (formerly HMR...
BioCentury | Sep 1, 2014
Clinical News

Alvocidib: Interim Phase II data

...Tolero Pharmaceuticals Inc. , Lehi, Utah Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alvocidib, flavopiridol (formerly HMR...
BioCentury | Apr 28, 2014
Clinical News

Alvocidib regulatory update

...Tolero Pharmaceuticals Inc. , Lehi, Utah Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alvocidib (flavopiridol) (formerly HMR...
BioCentury | Jan 6, 2014
Company News

Merck, HMR Weight Management Services Corp. endocrine/metabolic news

...On Dec. 20, 2013, Merck launched subsidiary HMR to provide weight management interventions that combine a...
...weight management interventions that combine a structured diet, behavior coaching and monitoring and physical activity. HMR...
...programs through a network of licensed clinics and through a remote delivery program. Merck said HMR...
Items per page:
1 - 10 of 316